SWOT Analysis for Medicamen Biotech Ltd. - Threats

Add SWOT widget to your site/app

Buy Zone: Stocks in the buy zone based on days traded at current PE and P/BV

Companies with high TTM EPS Growth

PEG lower than Industry PEG

Companies with Low Debt

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

Top Gainers

Promoter decreasing their shareholding

PE higher than Industry PE

Promoter holding decreased by more than -2% QoQ

New 52 week low today

High PE (PE > 40)

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

Lowest Momentum Scores (Technical Scores)

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Slowing Down Stocks (DVM)

Inefficient use of capital to generate profits - RoCE declining in the last 2 years

Inefficient use of shareholder funds - ROE declining in the last 2 years

Inefficient use of assets to generate profits - ROA declining in the last 2 years

Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years

Declining profits every quarter for the past 2 quarters

Low Piotroski Score : Companies with weak financials

Declining Net Cash Flow : Companies not able to generate net cash

Annual net profit declining for last 2 years

Weak Momentum: Price below Short, Medium and Long Term Averages

RSI indicating price weakness

Near 52 Week Low

Declining profitability: Falling ROCE

Stocks Underperforming their Industry Price Change in the Quarter

Red Flags: Weakening Technicals and Share Price Decline

Insiders sold stocks

Rising Delivery Percentage Compared to Prev Day

Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks

Declining Net Cash Flow and Cash from Operating Activity for last 2 years

Decline in Net Profit with falling Profit Margin (QoQ)

Decline in Quarterly Net Profit with falling Profit Margin (YoY)

New 52 Week Low